Full Name

Dr. Lucy Yan

Position

VP, Clinical Development

Quote

R552 is a potent and selective RIP1 kinase inhibitor that blocks inflammatory cell death downstream of death receptors. It is being developed at Rigel Pharmaceuticals for treatment of autoimmune and inflammatory disorders. We were very delighted to have Quotient Sciences on board and they worked with us on the formulation development as well as the first-in-human study of R552.

Company

Rigel Therapeutics